Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 284

1.

Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.

Shyangdan D, Clar C, Ghouri N, Henderson R, Gurung T, Preiss D, Sattar N, Fraser A, Waugh N.

Health Technol Assess. 2011 Nov;15(38):1-110. doi: 10.3310/hta15380. Review.

2.

Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis.

Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F.

Cochrane Database Syst Rev. 2007 Jan 24;(1):CD005166. Review.

PMID:
17253544
3.

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.

Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Review.

4.

Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status.

Stein LL, Dong MH, Loomba R.

Adv Ther. 2009 Oct;26(10):893-907. doi: 10.1007/s12325-009-0072-z. Epub 2009 Nov 16. Review.

PMID:
19921118
5.

Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

Eslami L, Merat S, Malekzadeh R, Nasseri-Moghaddam S, Aramin H.

Cochrane Database Syst Rev. 2013 Dec 27;(12):CD008623. doi: 10.1002/14651858.CD008623.pub2. Review.

PMID:
24374462
6.

[Therapeutic effects of insulin-sensitizing drugs on nonalcoholic fatty liver disease: experiment with rats].

Zhang DM, Zhang GY, Wang T, Zhong HJ, Chen WK.

Zhonghua Yi Xue Za Zhi. 2006 May 16;86(18):1279-83. Chinese.

PMID:
16796890
7.

Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials.

Musso G, Cassader M, Rosina F, Gambino R.

Diabetologia. 2012 Apr;55(4):885-904. doi: 10.1007/s00125-011-2446-4. Epub 2012 Jan 27. Review.

PMID:
22278337
8.

Insulin sensitizers in treatment of nonalcoholic fatty liver disease: Systematic review.

Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila FI, Sanchez-Avila F, Montano-Reyes MA, Uribe M.

World J Gastroenterol. 2006 Dec 28;12(48):7826-31. Review.

9.

Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review.

Socha P, Horvath A, Vajro P, Dziechciarz P, Dhawan A, Szajewska H.

J Pediatr Gastroenterol Nutr. 2009 May;48(5):587-96. doi: 10.1097/MPG.0b013e31818e04d1. Review.

PMID:
19412008
10.

Nonalcoholic fatty liver disease: current issues and novel treatment approaches.

Lomonaco R, Sunny NE, Bril F, Cusi K.

Drugs. 2013 Jan;73(1):1-14. doi: 10.1007/s40265-012-0004-0. Review.

PMID:
23329465
11.

Non-alcoholic steatohepatitis in children.

Nanda K.

Pediatr Transplant. 2004 Dec;8(6):613-8. Review.

PMID:
15598336
12.

Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis.

Gastaldelli A, Harrison SA, Belfort-Aguilar R, Hardies LJ, Balas B, Schenker S, Cusi K.

Hepatology. 2009 Oct;50(4):1087-93. doi: 10.1002/hep.23116.

PMID:
19670459
13.

Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design.

Chalasani NP, Sanyal AJ, Kowdley KV, Robuck PR, Hoofnagle J, Kleiner DE, Unalp A, Tonascia J; NASH CRN Research Group.

Contemp Clin Trials. 2009 Jan;30(1):88-96. doi: 10.1016/j.cct.2008.09.003. Epub 2008 Sep 10.

14.

The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis.

Mahady SE, Webster AC, Walker S, Sanyal A, George J.

J Hepatol. 2011 Dec;55(6):1383-90. doi: 10.1016/j.jhep.2011.03.016. Epub 2011 Apr 14. Review.

PMID:
21703200
15.

Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial.

Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, Scheimann AO, Sanyal AJ, Chalasani N, Tonascia J, Ünalp A, Clark JM, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; Nonalcoholic Steatohepatitis Clinical Research Network.

JAMA. 2011 Apr 27;305(16):1659-68. doi: 10.1001/jama.2011.520.

16.

Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation.

Czoski-Murray C, Warren E, Chilcott J, Beverley C, Psyllaki MA, Cowan J.

Health Technol Assess. 2004 Apr;8(13):iii, ix-x, 1-91. Review.

17.

Investigation of the effects of Chlorella vulgaris supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial.

Panahi Y, Ghamarchehreh ME, Beiraghdar F, Zare R, Jalalian HR, Sahebkar A.

Hepatogastroenterology. 2012 Oct;59(119):2099-2103. doi: 10.5754/hge10860.

PMID:
23234816
18.

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

J Clin Pharm Ther. 2006 Aug;31(4):375-83.

PMID:
16882108
19.

[Non-alcoholic fatty liver disease--new view].

Raszeja-Wyszomirska J, Lawniczak M, Marlicz W, Miezyńska-Kurtycz J, Milkiewicz P.

Pol Merkur Lekarski. 2008 Jun;24(144):568-71. Review. Polish.

PMID:
18702346
20.

Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial.

Haukeland JW, Konopski Z, Eggesbø HB, von Volkmann HL, Raschpichler G, Bjøro K, Haaland T, Løberg EM, Birkeland K.

Scand J Gastroenterol. 2009;44(7):853-60.

PMID:
19811343
Items per page

Supplemental Content

Write to the Help Desk